Enteris Bio Pharma
Pharmaceuticals, 83 Fulton St., Boonton, , 7005, New Jersey, United States, 11-50 Employees
Phone Number: 97********
Who is ENTERIS BIOPHARMA
Enteris BioPharma is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary oral drug delivery technologies. In addition to its ...
Read More
-
Headquarters: 83 Fulton St., Boonton, New Jersey, 7005, United States
-
Date Founded: 2013
-
Employees: 11-50
-
Revenue: $1 Billion and Over
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from ENTERIS BIOPHARMA
Enteris BioPharma Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Enteris BioPharma
Answer: Enteris BioPharma's headquarters are located at 83 Fulton St., Boonton, , 7005, New Jersey, United States
Answer: Enteris BioPharma's phone number is 97********
Answer: Enteris BioPharma's official website is https://enterisbiopharma.com
Answer: Enteris BioPharma's revenue is $1 Billion and Over
Answer: Enteris BioPharma's SIC: 2834
Answer: Enteris BioPharma's NAICS: 325412
Answer: Enteris BioPharma has 11-50 employees
Answer: Enteris BioPharma is in Pharmaceuticals
Answer: Enteris BioPharma contact info: Phone number: 97******** Website: https://enterisbiopharma.com
Answer: Enteris BioPharma is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary oral drug delivery technologies. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square foot GMP facility in Boonton, New Jersey, offering an expanding range of manufacturing and development services. Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (SWKH.OB). Since its founding in 2013, Enteris has advanced into the clinic multiple internal and external programs leveraging its Peptelligence platform. The technology has been developed and proven effective over the last decade to enable the oral delivery of peptide-based therapeutics as well as other molecules with low oral bioavailability. Enteris BioPharmas internal clinical product pipeline consists of Ovarest (oral leuprolide tablet), currently being evaluated in for endometriosis, and TobrateTM (oral tobramycin tablet) for the treatment of uncomplicated urinary tract infection (uUTI). External market analyses demonstrate projected annual U.S. revenue potential for these two products approximate $1 billion in aggregate. Additionally, Enteris BioPharmas oral peptide delivery technology is the subject of several active externally sponsored pre-clinical and clinical development programs, the most advanced of which include R-Pharms TBRIA, an oral calcitonin for patients with postmenopausal osteoporosis, and an oral formulation of Cara Therapeutics KORSUVATM, a potent peripheral kappa opioid receptor agonist with a primary focus for the treatment of pruritus.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month